Human Hepatocellular carcinoma (TLS11a) Aptamer Details
ID# 7672
Structure
Chemistry
DNA
Target
Human Hepatocellular carcinoma cell line (LH86)
Category
Cells
Affinity (Kd)
7.16 nM
Length
63
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-dApdCpdApdGpdCpdApdTpdCpdCpdCpdCpdApdTpdGpdTpdGpdApdApdCpdApdApdTpdCpdGpdCpdApdTpdTpdGpdTpdGpdApdTpdTpdGpdTpdTpdApdCpdGpdGpdTpdTpdTpdCpdCpdGpdCpdCpdTpdCpdApdTpdGpdGpdApdCpdGpdTpdGpdCpdTpdGp-3'
Molecular Weight: 19339.58
Extinction Coefficient: 589200
Binding Conditions / Buffer
Binding buffer (PBS containing 5 mM MgCl2, 4.5 mg/mL glucose, 0.1 mg/mL yeast tRNA, 1 mg/mL BSA)
Binding Temp: 4°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Meng, L. (2012). Targeted delivery of chemotherapy agents using liver cancer-specific aptamer. PloS One, 7(4), doi: 10.1371
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
